Pfizer has shut down the Phase III trial of figitumumab (CP-751,871) as first-line treatment in patients with advanced non-adenocarcinoma non-small cell lung cancer (NSCLC). The trial’s independent Data Safety Monitoring Committee (DSMC) concluded that adding figitumumab to paclitaxel plus carboplatin would be unlikely to meet the primary endpoint of improving overall survival compared to paclitaxel plus carboplatin alone. In September 2009, Pfizer stopped enrolling new patients i...